Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee scheduled for May 6 -- -- Novel orally administered checkpoint inhibitor CCX559 featured at American Association for Cancer Research Annual Meeting, expected to enter clinical development as a next generation cancer treatment in Q2 2021 --

ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights

MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on April 29, 2021 to discuss these results and to answer questions.

ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021

-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first half of 2021 --

ChemoCentryx's Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET. The event will feature a panel of key opinion leaders, a testimonial from a patient living with ANCA-associated vasculitis and members of the ChemoCentryx Management team. The event will focus on the Company's upcoming milestones and developments in key pipeline programs.

ChemoCentryx to Host Virtual R&D Day on April 14, 2021

ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in ChemoCentryx (CCXI): Can Its 8.6% Jump Turn into More Strength?

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company's Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.

ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.

ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2020 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q4 Loss, Misses Revenue Estimates

Shares of ChemoCentryx (NASDAQ:CCXI) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 65.38% year over year to ($0.43), which missed the estimate of ($0.33).

ChemoCentryx: Q4 Earnings Insights

-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E.U. (decision expected in H2 2021) and Japan --

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to discuss these results and to answer questions.

ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021

-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan's effects on kidney function, patient Quality of Life, and reduction in overall glucocorticoid-related toxicities also described --

ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

ChemoCentryx (CCXI) Reports Positive Top-Line Rare Disease Data

MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from the ACCOLADE clinical study, the largest, randomized, blinded, placebo-controlled trial in the ultra-rare kidney disease C3 Glomerulopathy (C3G) to date, which evaluated avacopan for the treatment of that disorder. Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor.

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

Why Is ChemoCentryx (CCXI) Up 2% Since Last Earnings Report?

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q3 Loss, Lags Revenue Estimates

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), which missed the estimate of ($0.31).

Recap: ChemoCentryx Q3 Earnings

-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) for avacopan in ANCA-associated vasculitis --

ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights

-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -- MOUNTAIN VIEW, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that ACR Convergence 2020 -- the virtual annual meeting of the American College of Rheumatology -- will feature a plenary session presentation today on the ADVOCATE Phase III trial results of the Company's lead drug candidate avacopan, an orally administered complement 5a receptor inhibitor, in the treatment of ANCA-associated vasculitis. A New Drug Application (NDA) for avacopan in ANCA-associated vasculitis is under review by the U.S. Food and Drug Administration.

ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis

ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for avacopan for the treatment of patients with ANCA-associated vasculitis (granulomatosis with polyangitis (GPA) and microscopic polyangiitis (MPA)), a group of rare and severe autoimmune diseases with high need for targeted therapies.

ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2020 to discuss these results and to answer questions.

News for Chemocentryx Stock (CCXI)